TIME CAP LABS supplier risk profile Q1-2026: 140 shipments, 4 suppliers, India-focused pharma imports.
TIME CAP LABS imported 140 shipments in Q1 2026 across 4 suppliers located in 2 countries. India accounted for 98.6% of shipments, with the remaining 1.4% sourced from the US. The importer's primary sourcing focus is pharmaceutical products (HS Chapter 30), led by suppliers MARKSANS PHARMA and M S MARKSANS PHARMA, both based in India.
Trigram screen against OFAC SDN, BIS Entity List, UFLPA Entity List, SAM Exclusions, EU FSF, UK HMT, UN SC, and 25+ allied jurisdictions.
Distance-screened against all 380 facilities in the ASPI Xinjiang Data Project. Proximity score: 100 / 100.
TIME CAP LABS registered zero matches against sanctions watchlists in Q1 2026. No suppliers in the sourcing network showed documented forced-labor exposure under UFLPA proximity screening.
4 distinct tier-1 suppliers in Q1 2026
| MARKSANS PHARMA | India | 120 |
| M S MARKSANS PHARMA | India | 17 |
| MARKSANS PHARMA | United States | 2 |
| COREL PHARMA CHEM INDIA | India | 1 |
Share of Q1 2026 inbound shipments by source country
2 tier-2 + 0 tier-3 nodes mapped - sign up to see them.
Free Tarifflo account unlocks the complete tier 1 / 2 / 3 supplier graph, daily refresh, alerts, and sanctions + UFLPA monitoring on every shipment.